Strides Pharma Science has struck a deal with fellow Indian firm Orbicular Pharmaceutical Technologies Private Limited to develop, manufacture and sell four nasal sprays for global markets. Citing IQVIA data, Strides said the four undisclosed nasal sprays had a combined market size “in excess of $400m.”
The strategic partnership will see the pair “leverage Orbicular’s advanced development capabilities with Strides’ US Food and Drug Administration approved manufacturing site for nasal sprays at Chestnut Ridge, New York,” with Strides ultimately planning to launch the products globally through its